Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   uniQure   /   Wat is de waarde van uniQure?

uniQure« Terug naar discussie overzicht

Wat is de waarde van uniQure?

Volgen
7.835 Posts
Pagina: «« 1 ... 276 277 278 279 280 ... 392 »» | Laatste | Omlaag ↓
  1. Vitavita 16 april 2017 09:50
    Wellicht berichtgeving over nieuwe ontwikkelingen tijdens de vele aanstaande conferenties/bijeenkomsten?

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced presentations at the following conferences taking place in April:

    World Orphan Drug Congress USA, April 19 - 21 2017, at the Washington Marriott Wardman Park in Washington D.C.

    Matt Kapusta, Chief Executive Officer, will be presenting a keynote address: Adeno-associated virus (AAV)-based gene therapies for rare, chronic and degenerative diseases, on Friday April 21st, 2017, 9.40 a.m. EDT.

    12th Annual HD Therapeutics Conference by CHDI, April 24 - 27 2017, at the Westin Dragonara Resort in St. Julian's, Malta.

    A presentation new preclinical data on huntingtin gene silencing in a mini-pig model of Huntington's Disease, using allele-specific and non-selective miRNAs, will be presented during the CHDI conference.

    Gene Therapy for Rare Disorders Conference, April 25 - 26 2017, at the Sheraton Boston Hotel, in Boston MA.

    Lance Weed, Vice President of US Operations, will be presenting: Optimizing the Scalability of Gene Therapy Manufacturing, on Tuesday April 25th, 2017, 2.00 p.m. EDT.
    Eileen Sawyer, Director of Global Medical Affairs, will be presenting: Bridging Gaps Through Early Integration of the Internal Medical Affairs Function, on Wednesday April 26th, 2017, 11.00 a.m. EDT.
    Daniel Leonard, Director of Global Patient Advocacy, will be presenting: The Intersection of Patient Advocacy and Gene Therapy: A Case Study in Hemophilia, on Wednesday April 26th, 2017, 2.00 p.m. EDT.

    Alliance for Regenerative Medicines (ARM)'s 5th Annual Cell & Gene Therapy Investor Day, April 27th 2017, at The State Room, in Boston MA.

    Matthew Kapusta, chief executive officer, will be participating in a fireside chat on Thursday, April 27th, 2017, 2.15 p.m. EDT.

    The Company also announced its participation in the following conferences taking place in April:

    Hemophilia Federation of America (HFA)'s Annual Symposium, April 6 - 9 2017, at the Rhode Island Convention Center in Providence, RI.

    The International Liver Congress 2017 by EASL, April 19 - 23 2017 at the RAI in Amsterdam, The Netherlands.

    Read more: www.nasdaq.com/press-release/uniqure-...
  2. Prof. Dollar 16 april 2017 11:11
    Ik heb er mijn bedenkingen bij; kwantiteit is geen kwaliteit. Nieuwe data Huntington kan mogelijk licht werpen op toegepaste vector. Waar blijven die 4DMT vectoren toch?! Want die nieuwe vectoren, promotors, indicaties en daadwerkelijk voordeel op time-to-market moeten ze echt snel een keer over de bühne brengen. Daarmee kunnen ze echt het verschil maken! Daarnaast hebben ze de verwachting uitgesproken om in de eerste helft van 2017 een update te geven over het Hemophilia A programma. Ook dat kan potentiële waarde genereren. Al die andere presentaties doen mijns inziens niet ter zake.
  3. Prof. Dollar 17 april 2017 10:16
    Alvast vooruit lopen op de een mogelijk Hemofilie A programma. Hoewel, ik zie QURE er voor aan het programma niet voort te zetten.

    Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A www.roche.com/media/store/releases/me...
  4. [verwijderd] 17 april 2017 12:38
    quote:

    Prof. Dollar schreef op 16 april 2017 11:11:

    Ik heb er mijn bedenkingen bij
    kwantiteit is geen kwaliteit
    moeten ze echt snel een keer over de bühne brengen
    Daarmee kunnen ze echt het verschil maken!
    Al die andere presentaties doen mijns inziens niet ter zake.
    Vroeger was u zakelijk; het begint nu een b-tje brompotterig te worden.
  8. Prof. Dollar 17 april 2017 21:02
    quote:

    Beurs2020 schreef op 17 april 2017 12:38:

    [...]
    Vroeger was u zakelijk; het begint nu een b-tje brompotterig te worden.
    Waarvan akte; toegegeven, enig cynisme is er inderdaad ingeslopen. Maar hoop doet leven. Zo hield QURE vorig jaar geen R&D Day. Deze wordt mogelijk medio Q3/Q4 wel weer georganiseerd. Een mooi moment voor ze om de 'closed box' te openen.
  12. forum rang 10 DeZwarteRidder 18 april 2017 16:54
    quote:

    Eeuwige Rijkdom schreef op 18 april 2017 16:52:

    Hij heeft ze waarschijnlijk om niet gekregen! Dus dat verlies valt mee . Wat lastiger is dat hij blijkbaar geen potentie ziet op korte termijn voor veel hoger. Of hij had direct cash nodig.?????
    Hij had geld nodig om Galapagos te kopen.....
    lol
  19. Prof. Dollar 20 april 2017 13:56
    Persbericht

    uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe

    -- Marketing Authorization for Glybera® to Expire on October 25, 2017 --

    -- Company Maintains Focus on Core Programs in Hemophilia B, Huntington's Disease and Congestive Heart Failure --

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will not pursue the renewal of the Glybera®(alipogene tiparvovec) marketing authorization in Europe when it is scheduled to expire on October 25, 2017.

    "The decision to not pursue marketing authorization renewal of Glybera in Europe involved a thoughtful and careful evaluation of patient needs and the clinical use of the therapy, and is not related to any risk-benefit concern," stated Matthew Kapusta, chief executive officer of uniQure. "Glybera's usage has been extremely limited and we do not envision patient demand increasing materially in the years ahead."

    Mr. Kapusta added, "In line with our previously announced strategy, we will focus our resources on advancing our hemophilia B program into a pivotal trial, moving our Huntington's disease program into a clinical proof-of-concept trial, and progressing our research and development collaboration with Bristol-Myers Squibb."

    In October 2012, the European Commission granted a five-year marketing authorization for Glybera under exceptional circumstances as a treatment for a small subset of patients with familial lipoprotein lipase deficiency (LPLD), an ultra-rare genetic disorder. As part of Glybera's approval, uniQure was required to establish a global registry for the long-term surveillance of patients, conduct a post-approval clinical study, submit for annual regulatory reassessments and implement additional risk management procedures. All of these activities required a significant infrastructure for uniQure that included the Company bearing the full costs of maintaining commercial manufacturing capabilities, managing development and validation of numerous assays and supporting regulatory interactions and inspections.

    uniQure has initiated discussions with the European Medicines Agency (EMA) to discuss steps to wind down these various activities and review plans for ongoing patient monitoring.

    Under the terms of the agreement between uniQure and Chiesi Group, which has exclusive rights for the commercialization of Glybera in Europe and other selected countries, uniQure will continue to make product available to Chiesi to treat any patients that are approved for treatment prior to October 25, 2017, and will also be responsible for terminating the Phase IV post-approval study.

    As a result of the withdrawal of Glybera, uniQure expects to reduce future expenses related to the product by approximately $2 million annually, beginning in 2018 and net of any payments to Chiesi. These cost savings will be in addition to those previously announced by the Company related to the consolidation of manufacturing into the Company's Lexington facility. uniQure continues to expect its existing cash resources will be sufficient to fund operations into 2019.
  20. forum rang 10 DeZwarteRidder 20 april 2017 14:00
    quote:

    Prof. Dollar schreef op 20 april 2017 13:56:

    Persbericht
    UniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe

    -- Marketing Authorization for Glybera® to Expire on October 25, 2017 --
    Dit debacle heb ik vele jaren geleden al voorspeld, toen de fans nog reclame maakten voor dit hopeloze en peperdure spul.
7.835 Posts
Pagina: «« 1 ... 276 277 278 279 280 ... 392 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
HEIJMANS KON 36,200 +2,85 +8,55%
Brunel 9,920 +0,46 +4,86%
ALLFUNDS GROUP 4,972 +0,11 +2,35%
JUST EAT TAKEAWAY 12,535 +0,29 +2,33%
JDE PEET'S 17,280 +0,36 +2,13%
PROSUS 45,905 +0,82 +1,81%
BAM 4,956 +0,09 +1,77%
INPOST 17,580 +0,27 +1,56%
Basic-Fit 22,600 +0,34 +1,53%
Galapagos 25,720 +0,38 +1,50%
IMCD 148,850 +1,95 +1,33%
ASCX 1.353,30 +17,47 +1,31%
EXOR NV 94,200 +1,20 +1,29%
Kendrion 10,380 +0,12 +1,17%
TomTom 4,520 +0,05 +1,12%
AALBERTS NV 36,460 +0,38 +1,05%
OCI 11,135 +0,12 +1,04%
FASTNED 20,150 +0,17 +0,85%
ArcelorMittal 27,040 +0,22 +0,82%
AMX 864,28 +6,96 +0,81%
ABN AMRO BANK N.V. 17,695 +0,14 +0,80%
ForFarmers 3,810 +0,03 +0,79%
ASMI 570,800 +4,40 +0,78%
SBM Offshore 20,940 +0,16 +0,77%
AMG Critical Materials N.V. 16,530 +0,12 +0,73%
Van Lanschot Kempen NV 48,650 +0,35 +0,72%
Philips Koninklijke 24,160 +0,16 +0,67%
ACOMO 18,340 +0,12 +0,66%
SIGNIFY NV 21,420 +0,14 +0,66%
Akzo Nobel 57,860 +0,36 +0,63%
Aegon 5,896 +0,03 +0,58%
Corbion 22,660 +0,12 +0,53%
Air France-KLM 8,412 +0,04 +0,53%
Aperam 29,580 +0,14 +0,48%
NSI 22,400 +0,10 +0,45%
Eurocommercial Properties 24,050 +0,10 +0,42%
UMG 28,260 +0,11 +0,39%
RANDSTAD NV 38,540 +0,15 +0,39%
ASR Nederland 48,840 +0,18 +0,37%
Sif Holding 11,180 +0,04 +0,36%
Ahold Delhaize 33,630 +0,12 +0,36%
B&S Group SA 4,320 +0,02 +0,35%
ASML 712,200 +2,30 +0,32%
Flow Traders 25,700 +0,06 +0,23%
Heineken 77,740 +0,18 +0,23%
Avantium 1,830 +0,00 +0,22%
RENEWI 10,260 +0,02 +0,20%
Sligro 10,600 +0,02 +0,19%
Vopak 39,760 +0,06 +0,15%
ING 16,460 +0,02 +0,12%
Fagron 19,400 +0,02 +0,10%
DSM FIRMENICH AG 100,800 +0,10 +0,10%
AEX 939,05 +0,47 +0,05%
Arcadis 50,400 0,00 0,00%
Nedap N.V. 60,000 0,00 0,00%
Pharming 0,875 0,00 0,00%
UNILEVER PLC 53,020 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
BESI 113,750 -3,25 -2,78%
PostNL 1,042 -0,03 -2,62%
NX FILTRATION 3,205 -0,07 -2,14%
WDP 20,960 -0,26 -1,23%
THEON INTERNAT 17,220 -0,20 -1,15%
NN Group 46,750 -0,52 -1,10%
EBUSCO HOLDING 0,620 -0,01 -1,02%
Accsys 0,491 0,00 -0,91%
SHELL PLC 32,310 -0,28 -0,86%
Fugro 14,370 -0,12 -0,83%
RELX 47,700 -0,38 -0,79%
VASTNED 28,100 -0,20 -0,71%
Wolters Kluwer 174,600 -0,90 -0,51%
Alfen N.V. 12,170 -0,03 -0,25%
CTP 16,300 -0,04 -0,24%
AZERION 1,636 0,00 -0,24%
TKH 37,380 -0,08 -0,21%
CM.COM 6,460 -0,01 -0,15%
Wereldhave 15,240 -0,02 -0,13%
KPN 3,480 0,00 -0,09%
ADYEN NV 1.803,800 -1,00 -0,06%
vlag naam koers verschil relatief verschil
AEX 939,05 +0,47 +0,05%
AEX GR 3.688,73 +0,58 +0,02%
DE40 22.314,65 0,00 0,00%
FTSE 100 8.676,65 +13,68 +0,16%
Europe50^ 5.461,03 0,00 0,00%
US30^ 44.242,10 +58,40 +0,13%
Nasd100^ 22.096,10 +26,50 +0,12%
US500^ 6.121,13 +1,95 +0,03%
Japan225^ 38.861,70 +275,90 +0,72%
VD-NEW 20,38 +0,50 +2,50%
#/^ Index indications calculated real time, zie disclaimer